Huangpu District Mayor Xian Yinsong visits Reforgene

On March 9, 2023, Xian Yinsong, District Mayor of Huangpu District, Guangzhou, led a delegation to Reforgene for research and guidance. Mayor Xian Yinsong first listened to the report by Dr. Liang Junbin, CEO of Reforgene, on the company's achievements in the field of innovative gene editing medicines, and praised the encouraging clinical research progress of the company's beta-thalassemia gene editing product.

Accompanied by Liang Junbin, Mayor Xian visited the company's GMP workshop and R&D center, and learned in detail about the development history and trends of gene editing technology and its application in disease treatment drug R&D. During the visit, Mayor Xian also listened to research scientists' introduction of the operational procedures of gene editing technology, and encouraged the company to accelerate R&D progress and promote the medicines to market as soon as possible to benefit more patients in restoring health.

Gene editing medicines are a new type of medicine with revolutionary significance, expected to bring hope and breakthroughs to more difficult-to-treat or incurable diseases.

Founded in 2019, Reforgene is a specialized, refined, distinctive and innovative SME key-cultivated by Guangzhou, and a Guangzhou Future Unicorn innovative enterprise. The company has strong technological innovation capability and a talent team, with a core underlying technology development platform and independent intellectual property rights. Upholding the philosophy of people-oriented innovation for life, the company is committed to providing patients with safe and effective curative gene editing innovative medicines. As a leading gene editing innovative medicine development enterprise in China, Reforgene is currently dedicated to the birth of innovative medicines for major refractory diseases of the blood system, ophthalmology and nervous system. The company has successfully developed the beta-thalassemia gene editing therapy product RM001, which has been approved by the NMPA to conduct Phase I clinical trials. RM001 is an innovative therapy product that activates HBG gene expression in autologous hematopoietic stem cells through editing technology, and is expected to provide thalassemia patients with a one-time, fundamental cure.